Virological outcomes in 85 women starting nucleoside-sparing therapy with darunavir/ritonavir and pregnancy outcome ≥22 WG, Monogest ANRS 168 study
| . | N . | % . | 95% CI . |
|---|---|---|---|
| Darunavir/ritonavir monotherapy changes before delivery | |||
| No change | 77 | 90.6 | 82.3–95.8 |
| Changed for intolerance | 2 | 2.4 | |
| Changed for inefficacy | 6 | 7.1 | |
| HIV-RNA at delivery (−8 to +7 days) | |||
| <50 copies/mL | 82 | 96.5 | 90.0–99.3 |
| >50 copies/mL | 0 | 0.0 | |
| Unknown at delivery (−8 to +7 days)a | 3 | 3.5 | |
| Last HIV-RNA at, or before, delivery | |||
| <50 copies/mL | 85 | 100.0 | 95.8 to <100 |
| Primary endpoint among 83 evaluable patients | |||
| With missing HIV-RNA at delivery = failure | |||
| Success | 75 | 90.4 | 81.9–95.7 |
| Failure (including 2 missing VL) | 8 | 9.6 | |
| With missing HIV-RNA at delivery as success | |||
| Success (VL < 50 copies/mL with no darunavir/ritonavir change) | 77 | 92.8 | 84.9–97.3 |
| Failure | 6 | 7.2 |
| . | N . | % . | 95% CI . |
|---|---|---|---|
| Darunavir/ritonavir monotherapy changes before delivery | |||
| No change | 77 | 90.6 | 82.3–95.8 |
| Changed for intolerance | 2 | 2.4 | |
| Changed for inefficacy | 6 | 7.1 | |
| HIV-RNA at delivery (−8 to +7 days) | |||
| <50 copies/mL | 82 | 96.5 | 90.0–99.3 |
| >50 copies/mL | 0 | 0.0 | |
| Unknown at delivery (−8 to +7 days)a | 3 | 3.5 | |
| Last HIV-RNA at, or before, delivery | |||
| <50 copies/mL | 85 | 100.0 | 95.8 to <100 |
| Primary endpoint among 83 evaluable patients | |||
| With missing HIV-RNA at delivery = failure | |||
| Success | 75 | 90.4 | 81.9–95.7 |
| Failure (including 2 missing VL) | 8 | 9.6 | |
| With missing HIV-RNA at delivery as success | |||
| Success (VL < 50 copies/mL with no darunavir/ritonavir change) | 77 | 92.8 | 84.9–97.3 |
| Failure | 6 | 7.2 |
One for consent withdrawn at 26 WG with last HIV-RNA <50 copies/mL at 26 WG; two with last available HIV-RNA at 13 and 33 days before delivery (both <50 copies/mL).
Virological outcomes in 85 women starting nucleoside-sparing therapy with darunavir/ritonavir and pregnancy outcome ≥22 WG, Monogest ANRS 168 study
| . | N . | % . | 95% CI . |
|---|---|---|---|
| Darunavir/ritonavir monotherapy changes before delivery | |||
| No change | 77 | 90.6 | 82.3–95.8 |
| Changed for intolerance | 2 | 2.4 | |
| Changed for inefficacy | 6 | 7.1 | |
| HIV-RNA at delivery (−8 to +7 days) | |||
| <50 copies/mL | 82 | 96.5 | 90.0–99.3 |
| >50 copies/mL | 0 | 0.0 | |
| Unknown at delivery (−8 to +7 days)a | 3 | 3.5 | |
| Last HIV-RNA at, or before, delivery | |||
| <50 copies/mL | 85 | 100.0 | 95.8 to <100 |
| Primary endpoint among 83 evaluable patients | |||
| With missing HIV-RNA at delivery = failure | |||
| Success | 75 | 90.4 | 81.9–95.7 |
| Failure (including 2 missing VL) | 8 | 9.6 | |
| With missing HIV-RNA at delivery as success | |||
| Success (VL < 50 copies/mL with no darunavir/ritonavir change) | 77 | 92.8 | 84.9–97.3 |
| Failure | 6 | 7.2 |
| . | N . | % . | 95% CI . |
|---|---|---|---|
| Darunavir/ritonavir monotherapy changes before delivery | |||
| No change | 77 | 90.6 | 82.3–95.8 |
| Changed for intolerance | 2 | 2.4 | |
| Changed for inefficacy | 6 | 7.1 | |
| HIV-RNA at delivery (−8 to +7 days) | |||
| <50 copies/mL | 82 | 96.5 | 90.0–99.3 |
| >50 copies/mL | 0 | 0.0 | |
| Unknown at delivery (−8 to +7 days)a | 3 | 3.5 | |
| Last HIV-RNA at, or before, delivery | |||
| <50 copies/mL | 85 | 100.0 | 95.8 to <100 |
| Primary endpoint among 83 evaluable patients | |||
| With missing HIV-RNA at delivery = failure | |||
| Success | 75 | 90.4 | 81.9–95.7 |
| Failure (including 2 missing VL) | 8 | 9.6 | |
| With missing HIV-RNA at delivery as success | |||
| Success (VL < 50 copies/mL with no darunavir/ritonavir change) | 77 | 92.8 | 84.9–97.3 |
| Failure | 6 | 7.2 |
One for consent withdrawn at 26 WG with last HIV-RNA <50 copies/mL at 26 WG; two with last available HIV-RNA at 13 and 33 days before delivery (both <50 copies/mL).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
